These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer. Bilgrami S, Feingold JM, Bona RD, Edwards RL, Khan AM, Rodriguez-Pinero F, Khan IA, Kazierad D, Clive J, Tutschka PJ. Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668 [Abstract] [Full Text] [Related]
3. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ. Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [Abstract] [Full Text] [Related]
4. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, Cooper DL. Bone Marrow Transplant; 2003 Dec; 32(12):1113-7. PubMed ID: 14647264 [Abstract] [Full Text] [Related]
5. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma]. Pokrovskaia OS, Mendeleeva LP, Urnova ES, Gaponova TV, Gribanova EO, Alekseeva IV, Drokov MIu, Kalinin NN, Gretsov EM, Kliasova GA, Savchenko VG. Ter Arkh; 2011 Dec; 83(7):50-7. PubMed ID: 21894752 [Abstract] [Full Text] [Related]
6. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Engelhardt M, Winkler J, Waller C, Lange W, Mertelsmann R, Henschler R. Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898 [Abstract] [Full Text] [Related]
7. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Gojo I, Guo C, Sarkodee-Adoo C, Meisenberg B, Fassas A, Rapoport AP, Cottler-Fox M, Heyman M, Takebe N, Tricot G. Bone Marrow Transplant; 2004 Jul; 34(1):69-76. PubMed ID: 15133484 [Abstract] [Full Text] [Related]
8. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. de la Rubia J, Bladé J, Lahuerta JJ, Ribera JM, Martínez R, Alegre A, García-Laraña J, Fernández P, Sureda A, de Arriba F, Carrera D, Besalduch J, García Boyero R, Palomera Bernal L, Hernández MT, García PR, Pérez-Calvo J, Alcalá A, Casado LF, San Miguel J. Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253 [Abstract] [Full Text] [Related]
12. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Hovenga S, de Wolf JT, Guikema JE, Klip H, Smit JW, Smit Sibinga CT, Bos NA, Vellenga E. Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257 [Abstract] [Full Text] [Related]
13. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Lazzarino M, Corso A, Barbarano L, Alessandrino EP, Cairoli R, Pinotti G, Ucci G, Uziel L, Rodeghiero F, Fava S, Ferrari D, Fiumanò M, Frigerio G, Isa L, Luraschi A, Montanara S, Morandi S, Perego D, Santagostino A, Savarè M, Vismara A, Morra E. Bone Marrow Transplant; 2001 Nov; 28(9):835-9. PubMed ID: 11781643 [Abstract] [Full Text] [Related]
14. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG. Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752 [Abstract] [Full Text] [Related]
15. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Zappasodi P, Nosari AM, Astori C, Ciapanna D, Bonfichi M, Varettoni M, Mangiacavalli S, Morra E, Lazzarino M, Corso A. Transfusion; 2008 May; 48(5):857-60. PubMed ID: 18248573 [Abstract] [Full Text] [Related]
16. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Lefrère F, Zohar S, Ghez D, Delarue R, Audat F, Suarez F, Hermine O, Damaj G, Maillard N, Ribeil JA, Azagury M, Misbahi R, Jondeau K, Cavazzana-Calvo M, Dal Cortivo L, Varet B. Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433 [Abstract] [Full Text] [Related]
17. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma. Dyson PG, Horvath N, Joshua D, Barrow L, Van Holst NG, Brown R, Gibson J, To LB. Bone Marrow Transplant; 2000 Jun; 25(11):1175-84. PubMed ID: 10849530 [Abstract] [Full Text] [Related]